EMPLOYEE NONCOMPETITION, NONDISCLOSURE AND DEVELOPMENTS AGREEMENTNondisclosure and Developments Agreement • April 13th, 2012 • Rib-X Pharmaceuticals, Inc. • Pharmaceutical preparations • Connecticut
This Employee Noncompetition, Nondisclosure and Developments Agreement (the “Agreement”) is entered into by and between the undersigned employee and Rib-X Pharmaceuticals, Inc., its parents, affiliates and subsidiaries (the “Company”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • April 13th, 2012 • Rib-X Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this day of , 20 , by and between Rib-X Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and (“Agent”).
December 1, 2011Rib-X Pharmaceuticals, Inc. • April 13th, 2012 • Pharmaceutical preparations • Connecticut
You are a key member of the senior management team of Rib-X Pharmaceuticals, Inc. (the “Company”). As a result, the Company is providing you with the following benefits in consideration of your continued employment with the Company.
YALE EXCLUSIVE LICENSE AGREEMENTYale Exclusive License Agreement • April 13th, 2012 • Rib-X Pharmaceuticals, Inc. • Pharmaceutical preparations • Connecticut
THIS AGREEMENT by and between YALE UNIVERSITY, a corporation organized and existing under, and by virtue of, a charter granted by the general assembly of the Colony and State of Connecticut and located in New Haven, Connecticut (“YALE”), and Rib-X Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, with principal offices located in Guilford, CT (“LICENSEE”) shall be effective upon the date of final execution below (“EFFECTIVE DATE”).
COLLABORATION AND LICENSE AGREEMENT by and between Rib-X Pharmaceuticals, Inc. and Sanofi Effective as of June 28, 2011Collaboration and License Agreement • April 13th, 2012 • Rib-X Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
For the sake of clarity, if a milestone related to a Clinical Trial or Regulatory Approval is reached with respect to a Licensed Product, then, upon such event (if not earlier), any earlier stage Clinical Trial milestones will also be deemed to have been reached with respect to such Licensed Product for purposes of this Section, whether or not such earlier milestone has actually occurred. For example, if Regulatory Approval for a Licensed Product is approved based on a Phase 2b Clinical Trial without a Phase 3 Clinical Trial, then upon Regulatory Approval, both the Regulatory Approval milestone and the initiation of a Phase 3 Clinical Trial milestone will be paid. Notwithstanding the foregoing, if any of the above milestones have been met with respect to a Licensed Product as to which Development is subsequently terminated in favor of [***] to such Licensed Compound, then Sanofi will not have any payment obligation with respect to achievement of those same completed milestones with res
RIB-X PHARMACEUTICALS, INC. EMPLOYEE NON-DISCLOSURE AND DEVELOPMENTS AGREEMENTRib-X Pharmaceuticals, Inc. • April 13th, 2012 • Pharmaceutical preparations • Delaware
As a condition of my employment with Rib-X Pharmaceuticals, Inc. its subsidiaries, affiliates, successors or assigns (together the “Company”), and in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by the Company, I agree to the following:
LICENSE AGREEMENTLicense Agreement • April 13th, 2012 • Rib-X Pharmaceuticals, Inc. • Pharmaceutical preparations
This Agreement (this “Agreement”) is made this twelfth day of May, 2006, by and between Wakunaga Pharmaceutical Co., Ltd. (hereinafter referred to as “WAKUNAGA”), a corporation duly organized and existing under the laws of Japan and having its principal office at 5-36, Miyahara 4-chome, Yodogawa-Ku, Osaka, Japan and Rib-X Pharmaceuticals, Inc. (hereinafter referred to as “RIB-X”), a corporation duly organized and existing under the laws of Delaware, U.S.A. and having its principal office at 300 George Street, Suite 301, New Haven, Conn., 06511 U.S.A.
LICENSE AND SUPPLY AGREEMENTLicense and Supply Agreement • April 13th, 2012 • Rib-X Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
WHEREAS, CyDex is engaged in the business of developing and commercializing novel drug delivery technologies designed to enhance the solubility and effectiveness of existing and development-stage drugs;
LICENCE AGREEMENTLicence Agreement • April 13th, 2012 • Rib-X Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.
PATENT PROSECUTION CONTROL AGREEMENTPatent Prosecution Control Agreement • April 13th, 2012 • Rib-X Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.
March 28, 2012Rib-X Pharmaceuticals, Inc. • April 13th, 2012 • Pharmaceutical preparations • Connecticut
You will be a key member of the senior management team of Rib-X Pharmaceuticals, Inc. (the “Company”) and as a result, the Company will provide you with the following benefits upon your initial employment with the Company.
EMPLOYMENT AGREEMENTEmployment Agreement • April 13th, 2012 • Rib-X Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS EMPLOYMENT AGREEMENT (hereinafter “this Agreement”) is made this 19th day of March 2010 between Rib-X Pharmaceuticals, Inc., a Delaware corporation, (hereinafter “the Company”) and Mark Leuchtenberger an individual who resides at 20 Old Farm Road, Newton, Massachusetts 02459 (hereinafter the “Executive”).
NON-STATUTORY STOCK OPTION AGREEMENTNon-Statutory Stock Option Agreement • April 13th, 2012 • Rib-X Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS STOCK OPTION AGREEMENT (this “Agreement”), effective as of the 19th day of March 2010 (the “Grant Date”), is between Rib-X Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Mark Leuchtenberger (“Participant”).
